Printer Friendly

Synthesis and anti-myocarditis activity in a multifunctional lanthanide microporous metal-organic framework with 1D helical chain building units.


Myocarditis, also known as inflammatory cardiomyopathy, is the inflammation of the heart muscle. Symptoms can include shortness of breath, chest pain, decreased ability to exercise, and an irregular heartbeat (1,2). The duration of problems can vary from hours to months. Complications may include heart failure due to dilated cardiomyopathy or cardiac arrest (3,4).

Metal-organic frameworks (MOFs) that are constructed by coordination of metal centers with multiorganic connectors represent an emerging class of inorganic-organic hybrid crystalline materials (5,6). Their structural tenability, well-defined single crystal architectures, functionalized pore environment and modifiable building blocks make them useful in many potential applications including biological activity, catalysis, and luminescent sensing materials (7-9). The organic ligand plays an important role in the construction of porous MOFs because it not only guides the formation of the secondary building units, but also determines the pore shapes and pore surroundings of the obtained products (10,11). MOFs prepared with ligands of high symmetry have been well studied because of synthetic and crystallographic considerations. As the elongated ligand of [H.sub.3]BTC, 1,3,5-benzenetrisbenzoic acid ([H.sub.3]BTB, Figure 1) has been widely used in the construction of porous MOFs (12,13). However, compared with the transition metal-BTB frameworks reported, the lanthanon metal-BTB frameworks are less studied (14).

Here, we present the synthesis and the structural analysis of a highly porous Yb-organic network [{Yb(BTB)([H.sub.2]O)] [(DEF).sub.2]}.sub.n] (1, DEF=N,N-diethylformamide). This MOF is composed of novel 1D helical chain building units and BT[B.sup.3]-ligand, which represents the first example of Ln-MOFs based on 1D helical chain building units. In addition, in vivo anti-myocarditis activity of compound 1 was investigated.

Material and Methods

Apparatus and materials

All the starting materials and reagents used in this work were obtained commercially and used without further purification. Element analyses (C, H, and N) were determined with an elemental Vairo EL III analyzer (Bruker, Germany). Powder X-ray diffraction data were collected using PANalytical X'Pert Pro powder diffractometer (Bruker) with Cu-K[alpha] radiation and 5[degrees] [less than or equal to] 20 [less than or equal to] 50[degrees]. Thermogravimetric experiments were performed using a TGA/NETZSCH STA449C instrument heated from 30 to 800[degrees]C (heating rate of 10[degrees]C/min, nitrogen stream; Bruker). Single crystal X-ray diffraction was carried out by an Oxford Xcalibur E diffractometer (Bruker).

Synthesis and characterization of [{[Yb(BTB)(H2O)] [(DEF).sub.2]}.sub.n] (1)

A mixture of Yb[(N[O.sub.3]).sub.2] x 6[H.sub.2]O (0.1 mmol, 0.031 g) and [H.sub.3]BTB (35 mg, 0.062 mmol) was added to a solution of DEF (4mL) and [H.sub.2]O (1 mL). The mixture was sealed in a Pyrex tube, and heated at 140[degrees]C for 3 days. After cooling to room temperature, the colorless polyhedral-shaped crystals formed were filtered, washed with DEF, and then dried in air. Analytical data for compound 1 ([C.sub.37][H.sub.39][N.sub.2] [O.sub.9]Yb): C, 53.23; H, 4.44; N, 3.29%. Calculated: C, 53.62; H, 4.74; N, 3.38%.

Crystal structure determination

Suitable single crystal of compound 1 was carefully selected under optical microscope and glued on thin glass fibers. The intensity data of 1 was collected on an Oxford Xcalibur E diffractometer. The empirical absorption corrections were applied to the data using the SADABS system. This structure was solved by direct method and refined by full-matrix least-squares method on F2 using the SHELXS-97 program (15). All non-hydrogen atoms of 1 were refined anistropically, and all the hydrogen atoms attached to carbon atoms were fixed at their ideal positions. Pertinent crystal data and structural refinement results for compound 1 are summarized in Table 1.

In vivo anti-myocarditis activity

C57BL6/j mice were involved in our experiment. A total of 48 eight-week-old male mice were divided into four groups: control + PBS (G1, n=12), control+ 1 (G2, n=12), CVB3 + PBS (G3, n=12), CVB3 + 1 (G4, n=12). G3 and G4 were infected by intraperitoneal (ip) injection of 1 x [10.sup.5] plaque forming units (pfu) Coxsackie virus B3 (CVB3) per mouse, while G1 and G2 received ip injection of phosphate-buffered saline (PBS) on the same day. Compound 1 was orally applied at 50 mg/kg on the next day of infection (G2 and G4), while G1 and G3 were orally administrated the same dose of PBS. Animals were housed with a normal diet, 12 h light/dark cycle, 30-70% humidity, and 20-25[degrees]C. All mice were sacrificed on day 7 post-CVB3 infection. We used a conductance catheter (DDS-307, Chang-Ai, China) to collect hemodynamic data (pressure and volume) before sacrificing the animals.

Statistical analysis was performed using Prism 6 (Bruker). One-way analysis of variance (ANOVA) was used for statistical analysis of the data with correction for multiple comparisons via the Tukey's range test. Data are reported as means [+ or -] SD. Differences were regarded to be significant if the two-sided P-value was lower than 0.05.

Results and Discussion

Molecular structure

The solvothermal reaction of Yb[(N[O.sub.3]).sub.3] x 6[H.sub.2]O and [H.sub.3]BTB in a mixed solvent of DEF and [H.sub.2]O provided complex 1 as colorless crystals. Single-crystal X-ray diffraction reveals that 1 crystallizes in a highly symmetric and chiral hexagonal space group P6122 and the 3-D coordination network is constructed through the connection of infinite 1-D helical chain building units and the BT[B.sup.3-] ligands. The asymmetric coordination unit consists of one Yb ion situated on a symmetry site with one half occupancy, half BT[B.sup.3-] ligand and one coordinated water molecule. As shown in Figure 2A, the Yb(III) ion is seven-coordinated by six carboxylic acid O atoms from six different BT[B.sup.3-] ligands and one coordinated water molecule, resulting in a pentagonal bipyramid geometry. The Yb-O bond distances are in the range of 2.212 (3) to 2.609 (5) A.

Each Yb atom is connected with the neighboring ones though three carboxylic groups. Such a connection mode leads to the formation of a 1D right-handed chain along a 61 axis, which represent a rare case of Ln-based helical chain building units according to the Cambridge Crystallographic Data Centre database (Figure 2B). The pitch of the helical chain is 21.832 (3) A. Furthermore, such 1D helical chain building units are further linked by BTB ligand through its three carboxylate groups to afford a 3D non-interpenetrating framework with 1D triangular channels with coordinated water molecule pointing to the channel center (Figure 2C). Based on the crystallographic data and considering the van derWaals radii of atoms, the pore size for the triangular channel is 5.4 [Angstrom]. To understand the network of 1 more clearly, we use the software TOPOS to simplify its framework. Each Yb(III) ion is connected with six O atoms from six different BTB- ligands and each BTB- ligand binds with six different Yb(III) ions. Thus, both of the Yb(III) ions and the BTB- ligand could be viewed as 6-connected nodes. In this case, the whole framework of 1 can be simplified to a 2-nodal (6,6)-connected network with the point symbol of ([4.sup.10] x [6.sup.5])([4.sup.7] x [6.sup.8]), which has not been observed in MOF chemistry (Figure 2D). The effective free volume of 1 without guest water molecules is 58.3% of the crystal volume (3569 [A.sup.3] of the 6126 [A.sup.3] unit cell volume), calculated with PLATON software.

Powder X-ray diffraction analysis (PXRD) and thermal analysis

PXRD experiment was carried out to verify the phase purity of the as-synthesized samples. As shown in Figure 3A, the diffraction peak of compound 1 is in good agreement with that of the simulated one based on the single crystal diffraction data, indicating the pure phase of the obtained samples. From the thermogravimetric curve of compound 1, we found that the first weight loss of 27.1% occurs from 25 to 210[degrees]C, which corresponds to the release of one coordinated water molecule and two lattice DEF molecules (Calcd: 26.5%). Then, the dissolved sample was stable up to 230[degrees]C, after which the framework began to collapse (Figure 3B).

In vivo anti-myocarditis activity

To evaluate the impact of compound 1 in CVB3-induced myocarditis, body weight, heart rate (HR), maximum left ventricle pressure (Pmax), maximum left ventricle pressure rise rate (dP/dtmax), and ejection fraction (EF) were analyzed in the present study. There was a significant difference in body weight between G3 and G1. Furthermore, there was a significant difference between G4 and G3 (Table 2). In comparison to G1 and G2, there was a sharp decrease in G3 animals in HR, Pmax, dP/dtmax and EF. Oppositely, G4 had a downward trend that compared to G1 and G2, but there was no significant difference between them (Table 3).

As known, human myocarditis can result in chest discomfort, palpitation, shortness of breath, dizziness, decreased activity, and poor appetite. CVB3-mice are a good myocarditis model that we can easily see reduced activity, and get body weight data through weighing; the decreased appetite indicates that the myocarditis model works. From our in vivo experiment, we found that the CVB3 group significantly lost body weight, but it seemed to reverse after application of compound 1. The CVB3 group had a significant decrease of HR, Pmax, dP/dtmax, and EF, which are essential factors of heart failure, especially systolic heart failure. In our investigation, compound 1 was effective in hemodynamics, indicating it could be a candidate for anti-myocarditis therapy.

In conclusion, we demonstrated the successful construction of a novel Yb-based MOF with 1D helical chain building units built up from 1,3,5-H3BTB ligand. Structural characterization suggests that this complex crystallizes in the hexagonal space group P6122 and possesses 1D triangular channels with coordinated water molecules pointing to the channel center. In addition, the results showed that compound 1 can improve hemodynamic parameters, and may be a good therapeutic compound for heart failure in the future.


(1.) Ghatnur SM, Parvatam G, Balaraman M. Culture conditions for production of biomass, adenosine, and cordycepin from cordyceps sinensis CS1197: optimization by desirability function method. Pharmacogn Mag 2015; 11 (Suppl 3): S448-S456, doi: 10.4103/0973-1296.168946.

(2.) Root-Bernstein R, Fairweather D. Unresolved issues in theories of autoimmune disease using myocarditis as a framework. J Theor Biol 2015; 375: 101-123, doi: 10.1016/ j.jtbi.2014.11.022.

(3.) Li-Sha G, Yi-He C, Na-Dan Z, Teng Z, Yue-Chun L. Effects of carvedilol treatment on cardiac cAMP response element binding protein expression and phosphorylation in acute coxsackievirus B3-induced myocarditis. BMC Cardiovasc Disord 2013; 13: 100, doi: 10.1186/1471-2261-13-100.

(4.) Massilamany C, Gangaplara A, Reddy J. Intricacies of cardiac damage in coxsackievirus B3 infection: Implications for therapy. Int J Cardiol 2014; 177: 330-339, doi: 10.1016/ j.ijcard.2014.09.136.

(5.) Krejci J, Mlejnek D, Sochorova D, Nemec P. Inflammatory cardiomyopathy: a current view on the pathophysiology, diagnosis, and treatment. Biomed Res Int 2016; 2016: 4087632, doi: 10.1155/2016/4087632.

(6.) Li-Sha G, Jing-Lin Z, Guang-Yi C, Li L, De-Pu Z, Yue-Chun L. Dose-dependent protective effect of nicotine in a murine model of viral myocarditis induced by coxsackievirus B3. Sci Rep 2015; 5: 15895, doi: 10.1038/srep15895.

(7.) Nyland JF, Fairweather D, Shirley DL, Davis SE, Rose NR, Silbergeld EK. Low-dose inorganic mercury increases severity and frequency of chronic coxsackievirus-induced autoimmune myocarditis in mice. Toxicol Sci 2012; 125: 134-143, doi: 10.1093/toxsci/kfr264.

(8.) Junghans U, Kobalz M, Erhart O, Preipler H, Lincke J, Mollmer J, Krautscheid H, Glaser R. A Series of robust copper-based triazolyl isophthalate MOFs: impact of linker functionalization on gas sorption and catalytic activity. Materials 2017; 10: 338, doi: 10.3390/ma10040338.

(9.) Haydar MAL, Abid HR, Sunderland B, Wang S. Metal organic frameworks as a drug delivery system for flurbi-profen. Drug Des Devel Ther 2017; 11: 2685-2695, doi: 10.2147/DDDT.S145716.

(10.) Han Q, Qi B, Ren W, He C, Niu J, Duan C. Polyoxometalate-based homochiral metal-organic frameworks for tandem asymmetric transformation of cyclic carbonates from olefins. Nat Commun 2015; 6: 10007, doi: 10.1038/ ncomms10007.

(11.) Kim JY, Jin M, Lee KJ, Cheon JY, Joo SH, Kim JM, et al. In situ-generated metal oxide catalyst during CO oxidation reaction transformed from redox-active metal-organic framework-supported palladium nanoparticles. Nanoscale Res Lett 2012; 7: 461, doi: 10.1186/1556-276X-7-461.

(12.) Wang Z, Wang J, Li M, Sun K, Liu C. Three-dimensional printed acrylonitrile butadiene styrene framework coated with Cu-BTC metal-organic frameworks for the removal of methylene blue. Sci Rep 2014; 4: 5939, doi: 10.1038/ srep05939.

(13.) Mitra J, Guerrero EN, Hegde PM, Wang H, Boldogh I, Rao KS, et al. New perspectives on oxidized genome damage and repair inhibition by pro-oxidant metals in neurological diseases. Biomolecules 2014; 4: 678-703, doi: 10.3390/ biom4030678.

(14.) Zhu Y, Zhu M, Xia L, Wu Y, Hua H, Xie J. Lanthanide metal-organic frameworks with six-coordinated ln(iii) ions and free functional organic sites for adsorptions and extensive catalytic activities. Sci Rep 2016; 6: 29728, doi: 10.1038/ srep29728.

(15.) Sheldrick GM. SHELXL-97, program for crystal structure solution and refinement. University of Gottingen: Gottingen, Germany; 1997.

Chenglv Hong [1], Xinlang Zhou [2], Weijian Huang[1], Peiren Shan [1] and Fengquan Dong [3]

[1] Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

[2] Department of Cardiology, Wenzhou City Hospital of Traditional Chinese Medicine and Western Medicine Combined, Wenzhou, Zhejiang, China

[3] Department of Cardiology, Shenzhen University General Hospital, Shenzhen, Guangdong, China

Correspondence: Fengquan Dong: <>

Received August 17, 2017 | Accepted November 10, 2017

doi: 10.1590/1414-431X20177050

Caption: Figure 1. Schematic representation of the [H.sub.3]BTB ligand used in this research

Caption: Figure 2. A, view of the asymmetric unit in compound 1 with 30% thermal ellipsoid level; B, view of 1D helical chain building units in 1; C, view of the 1D triangular channels in 1; D, (6,6)-connected topology for 1.

Caption: Figure 3. A, powder X-ray diffraction analysis patterns for compound 1. B, TGA curve for 1.
Table 1. Crystal data and structure refinements for compound 1.

Formula weight                      624.43
Temperature/K                       293 (2)
Crystal system                      hexagonal
Space group                         P6122
a/[Angstrom]                        18.0081 (15)
b/[Angstrom]                        18.0081 (15)
c/[Angstrom]                        21.8141 (13)
[alpha]/[degrees]                   90
[beta]/[degrees]                    90
[gamma]/[degrees]                   120
Volume/[[Angstrom].sup.3]           6126.4 (11)
Z                                   6
[sub.[rho]calc]g/[cm.sup.3]         1.016
[micro]/[mm.sup.-1]                 2.316
Radiation                           MoK [alpha]a ([lambda] =0.71073)
2[THETA] range for data             6.422 to 52.726
Reflections collected               16173
Independent reflections             4186 [[]=0.0485,
Data/restraints/parameters          4186/111/162
Goodness-of-fit on [F.sup.2]        1.018
Final R indexes [I>=2[sigma] (I)]   [R.sub.1]=0.0316, [omega]
Final R indexes [all data]          [R.sub.1]=0.0440, [omega]
Largest diff. peak/hole / e         0.42/-0.78
Flack parameter                     -0.026(10)
CCDC                                1573543

CCDC: Cambridge Crystallographic Data Centre.

Table 2. Body weight of mice at day 0 and day 7.

                  Control + PBS           Control +1

Day 0 BW (g)   24.83 [+ or -] 0.66    24.88 [+ or -] 0.69
Day 7 BW (g)   26.65 [+ or -] 0.49    26.37 [+ or -] 0.74

                     CVB3 + PBS                 CVB3+1

Day 0 BW (g)   24.88 [+ or -] 0.64      24.79 [+ or -] 0.59
Day 7 BW (g)   20.41 [+ or -] 0.73      22.41 [+ or -] 1.15
                      *(#)               *(#)(+)

Data are reported as means [+ or -]  SD. BW: body weight. CVB3:
Coxsackie virus B3; PBS: phosphate buffered saline. *P<0.01 vs
control + PBS, (#) P<0.01 vs control + 1, (+) P<0.01 vs CVB3
+PBS (one-way ANOVA).

Table 3. Hemodynamic data of mice.

                         Control + PBS                Control +1

HR (bpm)             531.48 [+ or -] 40.32      529.98 [+ or -] 39.46
Pmax (mmHg)          113.96 [+ or -] 21.64      109.66[+ or -]  12.91
dP/dtmax (mmHg/s)   9742.27 [+ or -] 1766.32   9445.64 [+ or -] 1920.23
EF (%)                78.60 [+ or -] 2.65        77.76 [+ or -] 5.20

                            CVB3 + PBS

HR (bpm)             386.77 [+ or -] 124.59 * (#)
Pmax (mmHg)          90.25 [+ or -]  22.37 * (#
) dP/dtmax (mmHg/s)   6108.48 [+ or -] 2592.93 * (#)
EF (%)                69.66 [+ or -]  7.74 * (#)


HR (bpm)             475.79 [+ or -] 79.13 (+)
Pmax (mmHg)           105.34 [+ or -] 11.43
dP/dtmax (mmHg/s)   8000.47 [+ or -] 1378.99
EF (%)                 73.64 [+ or -] 4.59

Data are reported as means [+ or -]  SD. HR: heart rate; Pmax: maximum
left ventricle pressure; dP/dtmax: maximum rate of rise of left
ventricle pressure; EF: ejection fraction; CVB3: coxsackie
virus B3; PBS: phosphate buffered saline. *P<0.05 vs control + PBS,
(#) P<0.05 vs control + compound 1, (+) P<0.01 vs CVB3+PBS (one-way
COPYRIGHT 2018 Associacao Brasileira de Divulgacao Cientifica (ABDC)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Hong, Chenglv; Zhou, Xinlang; Huang, Weijian; Shan, Peiren; Dong, Fengquan
Publication:Brazilian Journal of Medical and Biological Research
Article Type:Report
Date:Mar 1, 2018
Previous Article:Cardiac protein expression patterns are associated with distinct inborn exercise capacity in non-selectively bred rats.
Next Article:Lipid core nanoparticles resembling low-density lipoprotein and regression of atherosclerotic lesions: effects of particle size.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |